David Berry, MD, PhD is a Principal at Flagship Ventures. He joined Flagship in 2005 while completing his M.D. from Harvard Medical School. David was previously awarded a Ph.D. through the MIT Biological Engineering Division, where he studied the biological effects of complex sugars with advisors Professor Ram Sasisekharan and Professor Robert Langer. David also did his undergraduate work at MIT, graduating in 2000 Phi Beta Kappa and Sigma Xi, with a degree in brain and cognitive sciences.
He was named as a member of the MIT Corporation - its Board of Trustees - in 2006. David's work has led to 11 peer-reviewed publications, over 20 patents and applications, as well as over twenty-five awards and honors including the prestigious Lemelson-MIT Student Prize in 2005 for invention and innovation. David was also named as the Innovator of the Year by Technology Review in its 2007 TR35 list of world's top 35 innovators under the age of 35.
At Flagship, David focuses on investing in and founding early stage life science and cleantech ventures and works closely with portfolio companies BG Medicine, T2 Biosystems, Epitome Biosystems and LS9.
Really when I think about patents it's something that essential in an early stage company. It may not even protect what you're actually doing but it draws a line in the sand and it says that I have some sort of sense of ownership on this sort of idea. Most of the time when companies get mature, yo...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
